Journal
EXPERT REVIEW OF VACCINES
Volume 14, Issue 10, Pages 1331-1346Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.1078732
Keywords
effectiveness; efficacy; influenza vaccine; live attenuated influenza vaccine; school-age children
Categories
Funding
- MedImmune
- AstraZeneca
Ask authors/readers for more resources
Evidence of high efficacy of live attenuated influenza vaccine (LAIV) from randomized controlled trials is strong for children 2-6 years of age, but fewer data exist for older school-age children. We reviewed the published data on efficacy and effectiveness of LAIV in children >= 5 years. QUOSA (Elsevier database) was searched for articles published from January 1990 to June 2014 that included 'FluMist', 'LAIV', 'CAIV', 'cold adapted influenza vaccine', 'live attenuated influenza vaccine', 'live attenuated cold adapted' or 'flu mist'. Studies evaluated included randomized controlled trials, effectiveness and indirect protection studies. This review demonstrates that LAIV has considerable efficacy and effectiveness in school-age children.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available